National Center for Biotechnology Information’s Gene Expression Omnibus. This provided a link between available genomic data with the INRG database’s de-identified clinical patient infor- mation, such as basic demograph- ics, tumor profile, and treatment regimen. The searchable database now houses data from more than 19,000 neuroblastoma patients from around the world. “Gradually, we were starting to see the power of what we could do here,” Volchenboum said. Soon, he was being approached by pediatric researchers who hoped to create similar databases in other cancer types, demon- strating the need for a more com- prehensive data commons for all pediatric cancers. “Most of the commons for genomic data are not going to be undertaking the difficult task of harmonizing the clinical ele- ments, and I think that’s where this PCDC is going to be really valu- able,” he said. “This is the only way we’re going to be able to collect and share data between interna- tional groups.” With the appropriate funding, Volchenboum believes the team could get the PCDC up and run- ning in 2–3 years. He hopes it 2016 UChicago Medicine Pediatric Cancer Patients by Age and Disease Site Number of Patients 0–14 years old 15–19 years old S a l i v a r y S t o m a c h C o l o n T e s t i s R e c t u m K i d n e y B o n e E y e / O r b i t L e u k e m i a C r a n i a l N e r v e s / B r a i n L y m p h o m a T h y r o i d M e l a n o m a E n d o c r i n e S o f t T i s s u e 25 20 15 10 5 0 1 6 1 1 10 1 1 1 9 1 3 1 1 1 3 7 18 5 7 6 3 30 Powered by Innovation